secwatch.observer — SEC 8-K summary
======================================

Issuer:     SOLENO THERAPEUTICS INC (SLNO)
CIK:        0001484565
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001193125-25-275674
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Soleno initiates $100M accelerated share repurchase; amends loan facility
-------------------------------------------------------------------------

- Entered $100M accelerated share repurchase with Jefferies; initial delivery of ~1,511,553 shares.
- Repurchase expected to complete in Q1 2026; final shares based on VWAP less discount.
- Amended Oxford loan facility to permit ASR; $50M committed Term C/D loans removed; remaining $100M uncommitted.
- CEO cites Q3 2025 profitability and confidence in VYKAT XR launch as rationale for buyback.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1484565/000119312525275674/0001193125-25-275674-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1484565/000119312525275674/d63564d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-275674

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer